Dianthus Therapeutics, Inc. (DNTH)

Market Cap	638.33M
Revenue (ttm)	6.24M
Net Income (ttm)	-84.97M
Shares Out	32.13M
EPS (ttm)	-2.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,664
Open	18.66
Previous Close	18.27
Day's Range	18.42 - 20.33
52-Week Range	17.50 - 32.29
Beta	n/a
Analysts	Strong Buy
Price Target	54.33 (+172.33%)
Earnings Date	Mar 11, 2025

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2024, Dianthus Therapeutics's revenue was $6.24 million, an increase of 120.63% compared to the previous year's $2.83 million. Losses were -$84.97 million, 95.1% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price forecast is $54.33, which is an increase of 172.33% from the latest price.

Price Target

$54.33

(172.33% upside)

Analyst Consensus: Strong Buy